A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Percentage of Participants Who Experience Dose-limiting Toxicities (DLTs)

  Measured over: Cycle 1 (up to approximately 21 days); each cycle is 21 days

• Part 1: Percentage of Participants Who Experience an Adverse Event (AE)

  Measured over: Up to approximately 5 years

• Part 1: Percentage of Participants Who Discontinue Study Treatment Due to an AE

  Measured over: Up to approximately 5 years

• Part 1: Area Under the Curve (AUC) of total anti-HER3 antibody liquid chromatography-mass spectrometry (LC-MS) in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: AUC of anti-HER3 antibody-conjugated DXd (anti-HER3-ac-DXd) in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: AUC of DXd in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: Maximum Concentration (Cmax) of anti-HER3 antibody LC-MS in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: Cmax of anti-HER3-ac-DXd in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: Cmax of DXd in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: Concentration Immediately Before the Next Dose is Administered (Ctrough) of anti-HER3 antibody LC-MS in plasma

  Measured over: At designated timepoints (up to approximately 5 years)

• Part 1: Ctrough of anti-HER3-ac-DXd

Changes Tremor has spotted